NASDAQ$FDMT
4D Molecular Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
4D Molecular Therapeutics reported first quarter 2024 financial results and provided operational highlights.
4DMT reported a net loss of $32.4 million for Q1 2024, compared to a net loss of $28.7 million for Q1 2023. Cash, cash equivalents, and marketable securities were $589 million as of March 31, 2024, expected to fund operations into H1 2027.
- Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, enabling advancement into Phase 3 expected by Q1 2025.
- Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evaluating 4D-150 in broader wet AMD population expected to be presented at ASRS in July 2024.
- Interim clinical data from Phase 1/2 AEROW clinical trial expected to be presented at the European Cystic Fibrosis Society Conference in June 2024.
- Completed upsized public follow-on offering with total gross proceeds of $337 million, resulting in $589 million in cash and equivalents as of March 31, 2024.
Headline financials
Revenue & EPS history
4DMT · Revenue · Quarterly
$28K
Revenue by segment
4DMT · $20.2M total across 1 segment · Q3 2023
- Collaboration & license rev.$20.2M+3940.8%100.0%
Forward guidance
4DMT anticipates several milestones across its product pipeline.
Tailwinds
- Initial interim 24-week landmark analysis of Phase 2 PRISM Population Extension cohort expected at ASRS Annual Scientific Meeting on July 17-20, 2024.
- Update on Phase 3 clinical trial design for 4D-150 expected in Q3 2024.
- First Phase 3 clinical trial initiation for 4D-150 expected in Q1 2025.
- IND filing for 4D-175 expected in Q2 2024.
- Phase 1 initiation for 4D-175 expected in H2 2024.
Headwinds
- No specific negative guidance mentioned in the provided text.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+20.0%
Q3 2022
Best reaction
-10.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -0.7% | -17.3% | |
| Q4 2025 | +7.3% | +7.2% | +22.5% | |
| Q3 2025 | +6.7% | +6.1% | +7.4% | |
| Q1 2025 | +9.9% | +4.7% | +27.0% | |
| Q4 2024 | -8.6% | -8.6% | -28.7% | |
| Q3 2024 | +1.9% | +5.7% | -17.4% | |
| Q2 2024 | +0.6% | +1.6% | +2.4% | |
| Q1 2024 | -2.4% | -2.2% | -13.7% | |
| Q4 2023 | +5.3% | -3.0% | +14.2% | |
| Q3 2023 | +1.8% | +2.2% | +37.7% | |
| Q2 2023 | -1.6% | -1.1% | -7.4% | |
| Q1 2023 | -2.5% | +2.8% | +26.8% | |
| Q4 2022 | -0.7% | -5.4% | -12.5% | |
| Q3 2022 | +20.0% | +66.3% | +188.5% | |
| Q2 2022 | -10.4% | -12.5% | -14.9% | |
| Q1 2022 | -3.1% | -12.9% | -31.5% | |
| Q4 2021 | +8.1% | +1.6% | -22.5% | |
| Q3 2021 | -0.7% | -3.8% | -12.1% | |
| Q2 2021 | -4.0% | +5.2% | +19.4% | |
| Q1 2021 | -3.9% | -3.4% | +2.6% | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro